Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544204 | 1.00 | TMPRSS4 (0.36) | TMPRSS4KDRACP1AROTUD7B | |
| SCHEMBL18726901 | 0.88 | HTT (0.33) | TMPRSS4ACP1ARLMNA | |
| SCHEMBL15544951 | 0.87 | IDO1 (0.35) | IDO1 | |
| SCHEMBL15544948 | 0.87 | IDO1 (0.35) | IDO1 | |
| SCHEMBL15907321 | 0.86 | ACP1 (0.33) | TMPRSS4ACP1AR | |
| SCHEMBL16471329 | 0.86 | KDR (0.33) | TMPRSS4KDRARLMNARAPGEF3 | |
| SCHEMBL15544863 | 0.85 | MAP2K1 (0.34) | KDRARLMNARAPGEF3RAPGEF4 | |
| SCHEMBL16471301 | 0.84 | NPC1 (0.32) | LMNAIDO1 | |
| SCHEMBL15544255 | 0.82 | RAPGEF3 (0.43) | KDRARLMNARAPGEF3IDO1 | |
| SCHEMBL15544253 | 0.82 | RAPGEF3 (0.43) | KDRARLMNARAPGEF3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2964637-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9428469-B2 | Antiviral compounds | HOFFMANN-LA ROCHE (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160009666-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2964637-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2964633-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014135422-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009666-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TMPRSS4 1200/4885KDR 4550/4885ACP1 4436/4885 |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TMPRSS4 1031/4885KDR 4540/4885ACP1 4418/4885 |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TMPRSS4 1031/4885KDR 4540/4885ACP1 4418/4885 |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TMPRSS4 1166/4885KDR 4351/4885ACP1 4522/4885 |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TMPRSS4 1166/4885KDR 4351/4885ACP1 4522/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TMPRSS4 1166/4885KDR 4351/4885ACP1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.